By CreakyJoints Staff…A new abuse-deterrent label for EMBEDA, Pfizer’s morphine sulfate and naltrexone hydrochloride compound, was approved by the FDA, and is expected to reduce oral and intranasal (snorting) abuse when crushed, although it will not completely eliminate the possibility of abuse.

 

“More than one-third of extended-release opioids prescribed are morphine, and EMBEDA is the first extended-release morphine with the potential to reduce abuse via the oral and intranasal routes when crushed,” said Dr. Steven Romano, senior vice president and head, Medicines Development Group, Pfizer Global Innovative Pharmaceutical Business. “Pfizer believes that abuse-deterrent products, like EMBEDA, are important to help address the growing public health problem of opioid abuse in the U.S.”

Download Pfizer press release